Immunic, Inc. (IMUX)
IMUX Stock Price Chart
Explore Immunic, Inc. interactive price chart. Choose custom timeframes to analyze IMUX price movements and trends.
IMUX Company Profile
Discover essential business fundamentals and corporate details for Immunic, Inc. (IMUX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Apr 2014
Employees
91.00
CEO
Daniel Vitt
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
IMUX Financial Timeline
Browse a chronological timeline of Immunic, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 19 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.18.
Earnings released on 7 Aug 2025
EPS came in at -$0.20 falling short of the estimated -$0.18 by -11.11%.
Earnings released on 15 May 2025
EPS came in at -$0.25 matching the estimated -$0.25.
Earnings released on 27 Mar 2025
EPS came in at -$0.25 falling short of the estimated -$0.22 by -13.64%.
Earnings released on 7 Nov 2024
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%.
Earnings released on 8 Aug 2024
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.
Earnings released on 8 May 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%.
Earnings released on 22 Feb 2024
EPS came in at -$0.48 surpassing the estimated -$0.51 by +5.88%.
Earnings released on 14 Nov 2023
EPS came in at -$0.51 surpassing the estimated -$0.55 by +7.27%.
Earnings released on 3 Aug 2023
EPS came in at -$0.54 falling short of the estimated -$0.52 by -3.85%.
Earnings released on 11 May 2023
EPS came in at -$0.58 falling short of the estimated -$0.54 by -7.41%.
Earnings released on 23 Feb 2023
EPS came in at -$1.63 falling short of the estimated -$0.82 by -98.78%.
Earnings released on 3 Nov 2022
EPS came in at -$0.69 falling short of the estimated -$0.64 by -7.81%.
Earnings released on 4 Aug 2022
EPS came in at -$0.72 falling short of the estimated -$0.68 by -5.88%.
Earnings released on 10 May 2022
EPS came in at -$0.74 surpassing the estimated -$0.80 by +7.50%.
Earnings released on 24 Feb 2022
EPS came in at -$0.81 falling short of the estimated -$0.73 by -10.96%.
Earnings released on 4 Nov 2021
EPS came in at -$0.76 surpassing the estimated -$0.81 by +6.17%.
Earnings released on 6 Aug 2021
EPS came in at -$0.82 falling short of the estimated -$0.72 by -13.89%.
Earnings released on 6 May 2021
EPS came in at -$1.63 falling short of the estimated -$0.69 by -136.23%.
Earnings released on 26 Feb 2021
EPS came in at -$0.46 surpassing the estimated -$0.59 by +22.03%.
Earnings released on 5 Nov 2020
EPS came in at -$0.70 falling short of the estimated -$0.61 by -14.75%.
IMUX Stock Performance
Access detailed IMUX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.